霍普股份(301024.SZ):擬與控股子公司共同投設上海霍普光儲新能源
格隆匯6月5日丨霍普股份(301024.SZ)公佈,公司於2023年6月5日召開了第三屆董事會第十次會議,審議通過《關於與控股子公司共同投資設立子公司的議案》,同意公司與控股子公司江蘇愛珀科科技有限公司(以下簡稱“江蘇愛珀科”)共同投資設立“上海霍普光儲新能源有限公司”(暫定名稱,具體以工商登記為準),並授權公司管理層負責辦理本次設立子公司的相關事宜。公司以現金出資7000萬元,持股70%;江蘇愛珀科以現金出資3000萬元,持股30%。
截至公吿披露日,公司與控股子公司江蘇愛珀科尚未簽署合作協議,公司將在董事會審議通過後與江蘇愛珀科進行協商並適時簽署相關協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.